PBIO SEC फाइलिंग - Pressure BioSciences, Inc.- वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट, प्रॉस्पेक्टस

मूलभूत आँकड़े

CIK

830656

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pressure BioSciences, Inc.

SEC Filings (Chronological Order)

यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।

February 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report Pu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSURE BI
September 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition Report P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSURE B
August 19, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Tran
July 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 PRESSURE BIOSCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or Other Jurisdiction (Commission (I.R.S. Emp
July 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 PRESSURE BIOSCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or Other Jurisdiction (Commission (I.R.S. Emp
June 7, 2024	EX-21.1	Pressure BioSciences, Inc. – Subsidiaries PBI Agrochem, Inc. (Massachusetts) PBI BioSeq, Inc. (Massachusetts) Pressure BioSciences Europe (Poland) EXHIBIT 21.1 Pressure BioSciences, Inc. – Subsidiaries PBI Agrochem, Inc. (Massachusetts) PBI BioSeq, Inc. (Massachusetts) Pressure BioSciences Europe (Poland)
June 7, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38185 PRESSURE BIOSCI
May 17, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Tra
April 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 PRESSURE BIOSCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or Other Jurisdiction (Commission (I.R.S. Em
April 1, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐
February 27, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
January 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 PRESSURE BIOSCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation) (C
January 25, 2024	EX-99.1	Pressure BioSciences Announces Closing of Uncle Bud’s Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales Merged Companies Will Introduce Revolutionary New Product Capabilit Exhibit 99.1 FOR IMMEDIATE RELEASE Press Contacts: Richard T. Schumacher, President & CEO (508) 230-1828 (T) Jeffrey N. Peterson, Chairman (650) 812-8121 (T) Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T) Pressure BioSciences Announces Closing of Uncle Bud’s Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing
January 25, 2024	EX-10.1	Asset Purchase Agreement between Pressure BioSciences, Inc. and CBH International LLC, dated January 9, 2024.* Exhibit 10.1 ASSET PURCHASE AGREEMENT by and among PRESSURE BIOSCIENCES, INC. and CBH INTERNATIONAL LLC dated as of January 9, 2024 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”), dated as of January 9, 2024 (the “Effective Date”), is entered into between Pressure BioSciences, Inc., a Massachusetts company (“Buyer”), and CBH International LLC, a California limited liabil
November 20, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 ☐ Transition Repo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSU
November 20, 2023	EX-21.1	Securities Issuance and Exchange Agreement Exhibit 21.1 SECURITIES Issuance AND EXCHANGE AGREEMENT This Securities Issuance and Exchange Agreement (this “Agreement”) is dated as of February 28, 2023, between Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”), and Clayton A. Struve (the “Purchaser”). WHEREAS, the Company has determined that it is in its best interests to issue shares of a newly created series of Preferr
November 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐
October 24, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation
August 21, 2023	EX-21.1	Securities Issuance and Exchange Agreement Exhibit 21.1
August 21, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition Report Pu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSURE BI
August 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Tran
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition Report P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSURE B
May 5, 2023	EX-3.3	Certificate of Designation of Series CC Convertible Preferred Stock, filed May 1, 2023. Exhibit 3.3 CERTIFICATE OF DESIGNATION OF SERIES CC CONVERTIBLE PREFERRED STOCK OF PRESSURE BIOSCIENCES, INC. (PURSUANT TO SECTION 6.02 OF THE MASSACHUSETTS BUSINESS CORPORATION ACT, CHAPTER 156D OF THE MASSACHUSETTS GENERAL LAWS) 1. Series CC Preferred Stock Designation and Rank. (a) Designation. The designation of such series of the Preferred Stock shall be the Series CC Convertible Preferred St
May 5, 2023	EX-3.2	Certificate of Designation of Series BB Convertible Preferred Stock, filed May 1, 2023. Exhibit 3.2 CERTIFICATE OF DESIGNATION OF SERIES BB CONVERTIBLE PREFERRED STOCK OF PRESSURE BIOSCIENCES, INC. (PURSUANT TO SECTION 6.02 OF THE MASSACHUSETTS BUSINESS CORPORATION ACT, CHAPTER 156D OF THE MASSACHUSETTS GENERAL LAWS) 1. Series BB Preferred Stock Designation and Rank. (a) Designation. The designation of such series of the Preferred Stock shall be the Series BB Convertible Preferred St
May 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 PRESSURE BIOSCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation) (Co
May 5, 2023	EX-3.1	Articles of Amendment, filed May 1, 2023. Exhibit 3.1
April 12, 2023	EX-21.1	Pressure BioSciences, Inc. – Subsidiaries PBI Agrochem, Inc. (Massachusetts) PBI BioSeq, Inc. (Massachusetts) Pressure BioSciences Europe (Poland) EXHIBIT 21.1 Pressure BioSciences, Inc. – Subsidiaries PBI Agrochem, Inc. (Massachusetts) PBI BioSeq, Inc. (Massachusetts) Pressure BioSciences Europe (Poland)
April 12, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38185 PRESSURE BIOSCI
April 3, 2023	NT 10-K	Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐
March 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 PRESSURE BI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporatio
January 5, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2022 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or Other Jurisdiction (Commission (I.R.S.
December 6, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
November 21, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ☐ Transition Repo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSU
November 15, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2022 ☐
August 15, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ☐ Transition Report Pu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSURE BI
May 19, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ☐ Transition Report P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSURE B
May 17, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: May 12, 2023 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: March 31, 2022 ? Trans
April 5, 2022	EX-4.2	Description of securities registered under Section 12 of the Exchange Act of 1934 Exhibit 4.2 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is the description of the common stock, par value $0.01 per share (the ?Common Stock?) of Pressure BioSciences, Inc. (?we? or ?our?). The following description summarizes the most important terms of these securities. This summary does not purport to be complet
April 5, 2022	EX-10.2	2021 Equity Incentive Plan.* Exhibit 10.2 PRESSURE BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purpose and Eligibility. The purpose of this 2021 Equity Incentive Plan (the ?Plan?) of Pressure BioSciences, Inc., a Massachusetts corporation (the ?Company?) is to provide stock options, stock issuances and other equity interests in the Company (each, an ?Award?) to (a) employees, officers, directors, consultants and advisors
April 5, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38185 PRESSURE BIOSCI
April 5, 2022	EX-4.3	Form of Warrant Held by Convertible Note Holders Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 5, 2022	EX-21.1	List of Subsidiaries EXHIBIT 21.1 Pressure BioSciences, Inc. ? Subsidiaries PBI Agrochem, Inc. (Massachusetts) PBI BioSeq, Inc. (Massachusetts) Pressure BioSciences Europe (Poland)
April 5, 2022	EX-4.4	Form of Convertible Note Currently Outstanding Exhibit 4.4 CONFIDENTIAL PROMISSORY NOTE Twelve Month Fixed Rate (12%) Convertible Loan Loan Amount (Principal): $100,000 Points: 4.0 ($4,000 reduced from Principal) Cash-in Amount: $96,000 Interest: 1% per month, paid monthly on Principal ($1,000) Kicker: 10,000 shares restricted common stock ? earned upfront Closing Date: Friday, April 8, 2022 Due Date (Principal): April 8, 2023 Due Dates (Inter
April 5, 2022	EX-4.5	Form of Convertible Note Currently Outstanding Exhibit 4.5 TEMPLATE USE ONLY NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A
April 1, 2022	NT 10-K	Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2023 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: December 31, 2021 ?
January 4, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 PRESSURE BIOSCIENCES, Inc. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or Other Jurisdiction (Commission (I.R.S.
November 19, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
November 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ☐ Transition Repo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSU
November 16, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 202
August 20, 2021	EX-99.1	Pressure BioSciences, Inc. Investor Presentation Exhibit 99.1
August 20, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 18, 2021 PRESSURE BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) massachusetts (State or Other Jurisdiction of Incorporation) 001-38185 04-2652826 (Com
August 18, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ☐ Transition Report Pu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSURE BI
August 17, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: Jun
July 30, 2021	SC 13G/A	PBIO / Pressure Biosciences Inc / EAGLE EQUITIES LLC - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pressure BioSciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74112E208 (CUSIP Number) July 30, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
July 16, 2021	SC 13G	PBIO / Pressure Biosciences Inc / EAGLE EQUITIES LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Pressure BioSciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74112E208 (CUSIP Number) July 16, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 [ ] Transition Repo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSU
April 15, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38185 PRESSURE BI
April 15, 2021	EX-4.2	Description of securities registered under Section 12 of the Exchange Act of 1934 Exhibit 4.2 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is the description of the common stock, par value $0.01 per share (the ?Common Stock?) of Pressure BioSciences, Inc. (?we? or ?our?). The following description summarizes the most important terms of these securities. This summary does not purport to be complet
April 15, 2021	EX-21.1	List of Subsidiaries EXHIBIT 21.1 Pressure BioSciences, Inc. ? Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland)
April 1, 2021	NT 10-K	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: Dece
March 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Pressure BioSciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74112E208 (CUSIP Number) March 15, Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Pressure BioSciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74112E208 (CUSIP Number) March 15, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched
December 31, 2020	EX-10.1	Fourth Amendment to Binding Acquisition Letter of Intent by and between Pressure BioSciences, Inc. and Cannaworx, Inc., dated December 30, 2020 Exhibit 10.1 FOURTH AMENDMENT TO BINDING ACQUISITION LETTER OF INTENT THIS FOURTH AMENDMENT TO BINDING ACQUISITION LETTER OF INTENT (this “Amendment”), effective as of the 30th day of December 2020 (the “Effective Date”), is made by and between Pressure BioSciences, Inc., a Massachusetts corporation (“PBIO”), and Cannaworx, Inc., a Nevada corporation (“CWX”). WITNESSETH: WHEREAS, PBIO and CWX ente
December 31, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2020 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporatio
December 9, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2020 PRESSURE BIOSCIENCES, Inc. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or Other Jurisdiction (Commission (I.R.S.
November 16, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PR
November 6, 2020	EX-10.1	Third Amendment to Binding Acquisition Letter of Intent, Dated November 6, 2020 Exhibit 10.1 THIRD AMENDMENT TO BINDING ACQUISITION LETTER OF INTENT THIS THIRD AMENDMENT TO BINDING ACQUISITION LETTER OF INTENT (this “Amendment”), effective as of the 6th day of November 2020 (the “Effective Date”), is made by and between Pressure BioSciences, Inc., a Massachusetts corporation (“PBIO”), and Cannaworx, Inc., a Nevada corporation (“CWX”). WITNESSETH: WHEREAS, PBIO and CWX entered
November 6, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation
October 30, 2020	DEF 14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
October 9, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2020 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation)
October 9, 2020	EX-10.1	Second amendment to binding acquisition letter of intent, dated October 5, 2020 Exhibit 10.1 SECOND AMENDMENT TO BINDING ACQUISITION LETTER OF INTENT THIS SECOND AMENDMENT TO BINDING ACQUISITION LETTER OF INTENT (this “Amendment”), effective as of the 1st day of October 2020 (the “Effective Date”), is made by and between Pressure BioSciences, Inc., a Massachusetts corporation (“PBIO”), and Cannaworx, Inc., a Nevada corporation (“CWX”). WITNESSETH: WHEREAS, PBIO and CWX entere
August 14, 2020	EX-10.2	First Amendment to Binding Letter of Intent by and between Pressure BioSciences, Inc. and Cannaworx, Inc., dated July 6, 2020 Exhibit 10.2 FIRST AMENDMENT TO BINDING ACQUISITION LETTER OF INTENT THIS FIRST amendment TO BINDING ACQUISITION LETTER OF INTENT (this “Amendment”), effective as of the 6th day of July 2020 (the “Effective Date”), is made by and between Pressure BioSciences, Inc., a Massachusetts corporation (“PBIO”) and Cannaworx, Inc., a Nevada corporation (“CWX”). WITNESSETH: WHEREAS, PBIO and CWX entered into
August 14, 2020	EX-10.1	Binding Letter of Intent by and between Pressure BioSciences, Inc. and Cannaworx, Inc., dated April 29, 2020 Exhibit 10.1 Pressure BioSciences, Inc. and CannawoRx Binding Acquisition Letter of Intent The terms and conditions set forth herein are subject to change. The issuance and sale of securities and the closing of the proposed transactions is subject to completion of due diligence, preparation of definitive documentation, and the satisfaction of all pre-closing terms and conditions. Only those provis
August 14, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSUR
August 14, 2020	EX-10.4	Security Agreement, dated June 25, 2020, by and between Pressure BioSciences, Inc. and the U.S. Small Business Administration Exhibit 10.4 U.S. Small Business Administration Security Agreement SBA Loan #: 4135758009 Borrower: Pressure BioSciences, Inc. Secured Party: The Small Business Administration, an Agency of the U.S. Government Date: 06.25.2020 Note Amount: $150,000.00 1. DEFINITIONS. Unless otherwise specified, all terms used in this Agreement will have the meanings ascribed to them under the Official Text of the
August 14, 2020	EX-10.3	Economic Injury Disaster Loan Note, dated June 25, 2020, issued to the U.S. Small Business Administration Exhibit 10.3 U.S. Small Business Administration Note (Secured Disaster Loans) Date: 06.25.2020 Loan Amount: $150,000.00 Annual Interest Rate: 3.75% SBA Loan # 4135758009 Application #3300065448 1. PROMISE TO PAY: In return for a loan, Borrower promises to pay to the order of SBA the amount of one hundred and fifty thousand and 00/100 Dollars ($150,000.00), interest on the unpaid principal balance,
July 8, 2020	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2020 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation) (C
June 29, 2020	EX-10.3	Form of Amendment to Standstill and Forbearance Agreement entered into in each fiscal quarter of 2020 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on June 29, 2020) Exhibit 10.3 AMENDMENT TO STANDSTILL AND FORBEARANCE AGREEMENT This amendment TO STANDSTILL AND FORBEARANCE AGREEMENT (this “Amendment”), is made and executed as of XXXXX XX, 2020 by and among (i) PRESSURE BIOSCIENCES, INC., a corporation incorporated under the laws of the State of Massachusetts (the “Company”), and (ii) XXXXXXXXX, a (limited liability corporation) or (corporation) incorporated un
June 29, 2020	EX-10.2	Form of Standstill and Forbearance Agreement entered into in December 2019. Exhibit 10.2 STANDSTILL AND FORBEARANCE AGREEMENT THIS STANDSTILL AND FORBEARANCE AGREEMENT (the “Agreement”) is made and executed as of December xx, 2019, by and among (i) PRESSURE BIOSCIENCES, INC., a corporation incorporated under the laws of the State of Massachusetts (the “Company”), and (ii) XXXXXXXXX, a corporation incorporated under the laws of the State of XXXXX (the “Creditor”). W I T N
June 29, 2020	EX-10.1	Paycheck Protection Program Note, dated April 18, 2020, issued to North Easton Savings Bank Exhibit 10.1 U.S. Small Business Administration NOTE SBA Loan Name Pressure Biosciences, Inc. Date April 18, 2020 Loan Amount $367,039.00 Interest Rate 1.00% Borrower Pressure Biosciences, Inc. Operating Company N/A Lender North Easton Savings Bank, 20 Eastman Street, South Easton, MA 02375 1. PROMISE TO PAY: In return for the Loan, Borrower promises to pay to the order of Lender the amount of Thr
June 29, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSU
May 15, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation) (C
April 14, 2020	EX-21.1	List of Subsidiaries EXHIBIT 21.1 Pressure BioSciences, Inc. – Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland)
April 14, 2020	10-K	PBIO / Pressure BioSciences, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38185 PRESSURE BI
March 31, 2020	NT 10-K	PBIO / Pressure BioSciences, Inc. NT 10-K - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response.. 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: Decem
March 6, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2020 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation) (
February 5, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation
December 30, 2019	EX-10.1	Securities Purchase Agreement, dated December 20, 2019 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of the date listed on the signature pages hereto, is by and among Pressure BioSciences, Inc., a Massachusetts corporation with offices located at 14 Norfolk Avenue, South Easton, Massachusetts 02375 (the “Company”), and the investor signatory hereto (the “Purchaser”). RECITALS A. The Company a
December 30, 2019	EX-10.3	Common Stock Purchase Warrant, dated December 20, 2019 Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
December 30, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2019 PRESSURE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporatio
December 30, 2019	EX-10.5	Registration Rights Agreement, dated December 20, 2019 Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of the date listed on the signature pages hereto, is by and among Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”), and each of the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by
December 30, 2019	EX-10.4	General Security Agreement, dated December 20, 2019 Exhibit 10.4 GENERAL SECURITY AGREEMENT GENERAL SECURITY AGREEMENT dated December 20, 2019, made by Pressure BioSciences, Inc., a Massachusetts corporation (“Debtor”), and the undersigned lender set forth on Schedule A hereto, as supplemented from time to time (collectively, the “Secured Party”). Debtor hereby agrees in favor of Secured Party as follows: 1. In consideration for loans made or to be
December 30, 2019	EX-10.2	10% Senior Secured Convertible Promissory Note, dated December 20, 2019 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS
December 13, 2019	10-Q	PBIO / Pressure BioSciences, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PR
November 14, 2019	NT 10-Q	PBIO / Pressure BioSciences, Inc. NT 10-Q - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: Sep
November 6, 2019	DEF 14A	PBIO / Pressure BioSciences, Inc. DEF 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
September 20, 2019	EX-99.1	Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer Exhibit 99.1 Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team South Easton, MA, Sept. 17, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Compa
September 20, 2019	8-K	Financial Statements and Exhibits, Other Events, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 13, 2019 PRESSURE BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) MASSACHUSETTS (State or Other Jurisdiction of Incorporation) 001-38185 04-2652826 (
August 16, 2019	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 15, 2019 PRESSURE BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) MASSACHUSETTS (State or Other Jurisdiction of Incorporation) 001-38185 04-2652826 (Com
August 15, 2019	NT 10-Q	PBIO / Pressure BioSciences, Inc. NT 10-Q - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: Jun
August 15, 2019	10-Q	PBIO / Pressure BioSciences, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSUR
May 15, 2019	10-Q	PBIO / Pressure BioSciences, Inc. 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSU
May 1, 2019	EX-99.1	Pressure BioSciences Announces CEO Succession Plan Richard T. Schumacher to Step Down as President & CEO on September 9, 2019; Will Remain as Senior Consultant to Support Leadership Transition. FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President and CEO (508) 230-1828 (T) Jeffrey N. Peterson, Chairman of the Board (650) 812-8121 (T) Pressure BioSciences Announces CEO Succession Plan Richard T. Schumacher to Step Down as President & CEO on September 9, 2019; Will Remain as Senior Consultant to Support Leadership Transition. South Easton, MA, May 1, 2019 – Pressure Bi
May 1, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2019 PRESSURE BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) MASSACHUSETTS (State or Other Jurisdiction of Incorporation) 001-38185 04-2652826 (Comm
April 16, 2019	10-K	PBIO / Pressure BioSciences, Inc. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38185 PRESSURE BI
April 16, 2019	EX-21.1	List of Subsidiaries EXHIBIT 21.1 Pressure BioSciences, Inc. – Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland)
April 1, 2019	NT 10-K	PBIO / Pressure BioSciences, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response.. 2.50 SEC FILE NUMBER 001-38185 CUSIP NUMBER (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: Decem
February 15, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2019 PRESSURE BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) MASSACHUSETTS (State or Other Jurisdiction of Incorporation) 001-38185 04-2652826 (C
February 15, 2019	EX-3.1	Amended Certificate of Designation of Series AA Convertible Preferred Stock, filed February 14, 2019. CERTIFICATE OF DESIGNATION OF SERIES aa CONVERTIBLE PREFERRED STOCK OF PRESSURE BIOSCIENCES, INC.
December 17, 2018	EX-99.1	Pressure BioSciences, Inc. to Host Business Update on Wednesday, December 19th at 4:30 PM EST Pressure BioSciences, Inc. to Host Business Update on Wednesday, December 19th at 4:30 PM EST December 17, 2018 Update to Include Discussions on Recent Progress, Accomplishments, and Enhancements in All Three Platform Technologies; Commercialization and Strategic Partnership Efforts; Personnel Changes; and Q42018 & FY2019 Guidance SOUTH EASTON, MA / ACCESSWIRE / December 17, 2018 / Pressure BioSci
December 17, 2018	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2018 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation) (
December 12, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2018 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction (Commission (IRS Emp
November 14, 2018	8-K	Regulation FD Disclosure 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2018 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction o
November 14, 2018	10-Q	PBIO / Pressure BioSciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PR
October 22, 2018	DEFA14A	PBIO / Pressure BioSciences, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)
October 22, 2018	DEF 14A	PBIO / Pressure BioSciences, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
August 14, 2018	10-Q	PBIO / Pressure BioSciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSUR
June 15, 2018	EX-10.3	Form of Letter Agreement to Convert Line of Credit VIA ELECTRONIC MAIL Re: Agreement to Amend Conversion Price and Convert – LOC Obligation; Agreement to Amend Line of Credit Warrants Dear Investor: Reference is made to that certain October 26, 2016 Promissory Note, as amended pursuant to Amendment 1 on May 2, 2017, Amendment 2 on August 18, 2017, and Amendment 3 on January 30, 2018, in the Principal Amount of $4,000,000 (the “Promissory Note”) issued by the Company to you and Common Stock Purchase Warrants issued in connection therewith (the “Line of Credit Warrants” and, together with the Promissory Note, the “Line of Credit Documents”).
June 15, 2018	EX-10.2	Form of Letter Agreement to Convert Debentures VIA ELECTRONIC MAIL Re: Agreement to Convert Debentures; Agreement to Amend Debenture Warrants; Agreement to Receive New Warrants Dear Investor: Reference is made to that certain Subscription Agreement (the “Subscription Agreement”), entered into between July 22, 2015 and March 31, 2016 by and among Pressure BioSciences, Inc.
June 15, 2018	EX-4.1	Form of Warrant issued in connection with debt conversion NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM
June 15, 2018	EX-99.1	Pressure BioSciences Converts Additional $7.24M of Debt into Equity: Total Conversions Exceed $13.6M in Past 30 Days Pressure BioSciences Converts Additional $7.24M of Debt into Equity: Total Conversions Exceed $13.6M in Past 30 Days June 12, 2018 2015/2016 Debentures, Line-of-Credit, Promissory Note, & Misc. Short-Term Debt All Converted into Equity; Investors Signal Strong Support for Company’s Planned 2018 Up-List SOUTH EASTON, MA / ACCESSWIRE / June 12, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI”
June 15, 2018	EX-10.1	Form of Letter Agreement to Convert May 2017 Promissory Note VIA ELECTRONIC MAIL Re: Agreement to Convert – May 2017 Promissory Note Obligation Dear Investor: Reference is made to that certain May 19, 2017 Promissory Note, in the Principal Amount of $630,000 (the “Promissory Note”), issued by the Company to you (the “May 2017 Promissory Note Documents”).
June 15, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2018 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation) (Comm
May 15, 2018	10-Q	PBIO / Pressure BioSciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PRESSU
May 15, 2018	EX-3.1	Certificate of Designation of Series AA Convertible Preferred Stock, filed May 1, 2018 1. Series AA Preferred Stock Designation and Rank. (a) Designation. The designation of such series of the Preferred Stock shall be the Series AA Convertible Preferred Stock, par value $0.01 per share (the “Series AA Preferred Stock”). The maximum number of shares of Series AA Preferred Stock shall be Ten Thousand (10,000) shares. (b) Rank. The Series AA Preferred Stock shall rank prior to the comm
May 15, 2018	EX-10.1	Amendment Number 3 to October 26 Promissory Note, dated January 30, 2018 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
April 2, 2018	10-K	PBIO / Pressure BioSciences, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38185 PRESSURE BI
April 2, 2018	EX-21.1	List of Subsidiaries EXHIBIT 21.1 Pressure BioSciences, Inc. – Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland)
April 2, 2018	EX-10.22	Amendment Number 2 to October 26 Promissory Note, dated May 2, 2017 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
December 27, 2017	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2017 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction (Commission (IRS Em
December 18, 2017	EX-10.1	Asset Purchase Agreement between Pressure BioSciences, Inc. and BaroFold, Inc., dated December 12, 2017.* ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this ?Agreement?), is made as of December 12, 2017, by and between Barofold, Inc.
December 18, 2017	EX-99.1	Pressure BioSciences Announces Acquisition of All Assets of BaroFold, Inc. Acquisition to Combine BaroFold’s Patented High-Pressure Protein Refolding Technology with PBI’s Leadership in High-Pressure Instrumentation and Worldwide Market Access. Compa FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President & CEO (508) 230-1828 (T) Jeffrey N. Peterson, Chairman of the Board (650) 812-8121 (T) Pressure BioSciences Announces Acquisition of All Assets of BaroFold, Inc. Acquisition to Combine BaroFold?s Patented High-Pressure Protein Refolding Technology with PBI?s Leadership in High-Pressure Instrumentation and Worldwide Market Ac
December 18, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2017 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 001-38185 04-2652826 (State or other jurisdiction of incorporation) (
November 17, 2017	DEF 14A	PBIO / Pressure BioSciences, Inc. 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
November 13, 2017	10-Q	PBIO / Pressure BioSciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38185 PR
August 15, 2017	RW	Pressure BioSciences Pressure BioSciences, Inc. 14 Norfolk Avenue South Easton, MA 02375 August 15, 2017 VIA EDGAR Amanda Ravitz, Assistant Director Office of Electronics and Machinery Mail Stop 3030 Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Pressure BioSciences, Inc. (the ?Company?) Registration Statement on Form S-1 (File No. 333-215277) and Form
August 14, 2017	10-Q	PBIO / Pressure BioSciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-21615 PRESSUR
August 10, 2017	8-A12B	Pressure BioSciences 2B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 04-2652826 (State of incorporation or organization) (I.R.S. Employer Identification No.) 14 Norfolk
August 10, 2017	EX-4.5	WARRANT AGENT AGREEMENT EX-4.5 3 ex4-5.htm WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of , 2017 (the “Issuance Date”) between Pressure BioSciences, Inc., a company incorporated under the laws of the Commonwealth of Massachusetts (the “Company”), and Computershare Trust Company, N.A. (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Unde
August 10, 2017	S-1/A	As filed with the Securities and Exchange Commission on August 9 , 2017 As filed with the Securities and Exchange Commission on August 9 , 2017 Registration No.
August 10, 2017	EX-1.1	UNDERWRITING AGREEMENT PRESSURE BIOSCIENCES, INC. JOSEPH GUNNAR & CO., LLC as Representative of the Several Underwriters PRESSURE BIOSCIENCES, INC. UNDERWRITING AGREEMENT UNDERWRITING AGREEMENT Between PRESSURE BIOSCIENCES, INC. and JOSEPH GUNNAR & CO., LLC as Representative of the Several Underwriters PRESSURE BIOSCIENCES, INC. UNDERWRITING AGREEMENT New York, New York , 2017 Joseph Gunnar & Co., LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 30 Broad Street, 11th Floor New York, NY 10004 Ladies and Gentlemen: The undersigned
June 29, 2017	S-1/A	As filed with the Securities and Exchange Commission on June 28, 2017 As filed with the Securities and Exchange Commission on June 28, 2017 Registration No.
June 28, 2017	S-1/A	As filed with the Securities and Exchange Commission on June 28 , 2017 As filed with the Securities and Exchange Commission on June 28 , 2017 Registration No.
June 22, 2017	EX-10.3	*REMAINDER OF PAGE INTENTIONALLY LEFT BLANK* June 2, 2017 VIA ELECTRONIC MAIL Re: Agreement to Amend Conversion Price and Convert ? Debentures; Agreement to Amend Debenture Warrants; Receipt of Shares Dear Investor: Reference is made to that certain Subscription Agreement (the ?Subscription Agreement?), entered into between July 22, 2015 and March 31, 2016 by and among Pressure BioSciences, Inc.
June 22, 2017	EX-10.2	*REMAINDER OF PAGE INTENTIONALLY LEFT BLANK* VIA ELECTRONIC MAIL Re: Agreement to Amend Conversion Price and Convert ? Debentures; Agreement to Amend Debenture Warrants Dear Investor: Reference is made to that certain Subscription Agreement (the ?Subscription Agreement?), entered into between July 22, 2015 and March 31, 2016 by and among Pressure BioSciences, Inc.
June 22, 2017	EX-10.1	*REMAINDER OF PAGE INTENTIONALLY LEFT BLANK* June 8, 2017 VIA ELECTRONIC MAIL Re: Agreement to Convert ? Series D Preferred Stock; Receipt of Warrant; Dear: Reference is made to the 75 shares of Series D Preferred Stock (the ?Preferred Stock?) issued by Pressure BioSciences, Inc.
June 22, 2017	EX-10.4	*REMAINDER OF PAGE INTENTIONALLY LEFT BLANK* VIA ELECTRONIC MAIL Re: Agreement to Amend Conversion Price and Convert ? Debentures; Agreement to Amend Debenture Warrants; Agreement to Convert Promissory Note; Agreement to Amend Line of Credit Warrants; Agreement to Convert Preferred Stock.
June 22, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2017 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Comm
June 16, 2017	S-1/A	As filed with the Securities and Exchange Commission on June 16 , 2017 As filed with the Securities and Exchange Commission on June 16 , 2017 Registration No.
June 16, 2017	EX-10.15	*REMAINDER OF PAGE INTENTIONALLY LEFT BLANK* VIA ELECTRONIC MAIL Re: Agreement to Amend Conversion Price and Convert ? Debentures; Agreement to Amend Debenture Warrants Dear Investor: Reference is made to that certain Subscription Agreement (the ?Subscription Agreement?), entered into between July 22, 2015 and March 31, 2016 by and among Pressure BioSciences, Inc.
June 16, 2017	EX-10.14	*REMAINDER OF PAGE INTENTIONALLY LEFT BLANK* EX-10.14 2 ex10-14.htm June 8, 2017 VIA ELECTRONIC MAIL Re: Agreement to Convert – Series D Preferred Stock; Receipt of Warrant; Dear: Reference is made to the 75 shares of Series D Preferred Stock (the “Preferred Stock”) issued by Pressure BioSciences, Inc. (the “Company”) to you in November 2011. The Company expects to undertake a 1 for 30 reverse stock split on Monday, June 5, 2017. Unless the
June 16, 2017	EX-10.16	*REMAINDER OF PAGE INTENTIONALLY LEFT BLANK* June 2, 2017 VIA ELECTRONIC MAIL Re: Agreement to Amend Conversion Price and Convert ? Debentures; Agreement to Amend Debenture Warrants; Receipt of Shares Dear Investor: Reference is made to that certain Subscription Agreement (the ?Subscription Agreement?), entered into between July 22, 2015 and March 31, 2016 by and among Pressure BioSciences, Inc.
June 16, 2017	EX-21.1	Pressure BioSciences, Inc. - Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland) EX-21.1 6 ex21-1.htm Exhibit 21.1 Pressure BioSciences, Inc. - Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland)
June 16, 2017	EX-10.17	*REMAINDER OF PAGE INTENTIONALLY LEFT BLANK* VIA ELECTRONIC MAIL Re: Agreement to Amend Conversion Price and Convert ? Debentures; Agreement to Amend Debenture Warrants; Agreement to Convert Promissory Note; Agreement to Amend Line of Credit Warrants; Agreement to Convert Preferred Stock.
May 26, 2017	EX-10.1	Amendment Number 1 to October 26 Promissory Note, dated May 2, 2017 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
May 26, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2017 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Commis
May 26, 2017	EX-10.2	Asset Purchase Agreement between Pressure BioSciences, Inc. and BaroFold, Inc., dated December 12, 2017. NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
May 16, 2017	NT 10-Q	Pressure BioSciences 0-Q UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.
May 16, 2017	EX-10.2	Securities Purchase Agreement dated March 14, 2017 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March , 2017, between Pressure BioSciences, Inc.
May 16, 2017	EX-10.1	Amendment to the July 1, 2016 $200,000 Convertible Note between Vision Capital and Pressure BioSciences, Inc. AMENDMENT TO THE JULY 1, 2016 $200,000 CONVERTIBLE NOTE BETWEEN VISION CAPITAL AND PRESSURE BIOSCIENCES, INC.
May 16, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 [ ] Transition Repo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-21615 PRESSU
April 24, 2017	EX-4.1	Form of Debenture NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE
April 24, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2017 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Com
April 24, 2017	EX-10.2	Letter Agreement, dated April 19, 2017 April 19, 2017 Bellridge Capital LP Gentlemen: Reference is made to the certain Securities Purchase Agreement dated as of March 14, 2017 (the ?Securities Purchase Agreement?) between Pressure BioSciences, Inc.
April 24, 2017	EX-10.1	Securities Purchase Agreement, dated March 14, 2017 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March , 2017, between Pressure BioSciences, Inc.
April 14, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 10, 2017 PRESSURE BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) MASSACHUSETTS (State or Other Jurisdiction of Incorporation) 000-21615 04-2652826 (Comm
April 11, 2017	S-1/A	As filed with the Securities and Exchange Commission on April 11 , 2017 As filed with the Securities and Exchange Commission on April 11 , 2017 Registration No.
April 11, 2017	EX-21.1	Pressure BioSciences, Inc. - Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland) Exhibit 21.1 Pressure BioSciences, Inc. - Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland)
March 22, 2017	EX-10.13	2015 Nonqualified Stock Option Plan.* PRESSURE BIOSCIENCES, INC. 2015 Nonqualified Stock Option Plan 1. Purpose and Eligibility. The purpose of this 2015 Nonqualified Stock Option Plan (the “Plan”) of Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”) is to provide nonqualified stock options in the Company (each, an “Award”) to (a) employees, officers, directors, consultants and advisors of the Company and its Par
March 22, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2016 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 000-21615 PRESSURE BI
March 22, 2017	EX-21.1	Pressure BioSciences, Inc. - Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland) EXHIBIT 21.1 Pressure BioSciences, Inc. - Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland)
December 28, 2016	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2016 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction (Commission (IRS Em
December 22, 2016	S-1	As filed with the Securities and Exchange Commission on December 22, 2016 As filed with the Securities and Exchange Commission on December 22, 2016 Registration No.
December 22, 2016	EX-21.1	Pressure BioSciences, Inc. - Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland) Exhibit 21.1 Pressure BioSciences, Inc. - Subsidiaries PBI BioSeq, Inc. (U.S.A.) Pressure BioSciences Europe (Poland)
November 15, 2016	NT 10-Q	Pressure BioSciences 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response?...????... 2.50 SEC FILE NUMBER 000-21615 CUSIP NUMBER (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended
November 14, 2016	DEF 14A	Pressure BioSciences 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
November 14, 2016	EX-10.1	Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of the date listed on the signature pages hereto, is by and among Pressure Biosciences, Inc., a Massachusetts corporation with offices located at 14 Norfolk Avenue, South Easton, Massachusetts 02375 (the ”Company”), and the investors listed on the Schedule of Purchasers attached hereto (indivi
November 14, 2016	EX-4.1	COMMON STOCK PURCHASE WARRANT PRESSURE BIOSCIENCES, INC. Warrant No. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
November 14, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 [ ] Transition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-21615 PR
November 3, 2016	EX-4.1	Form of Warrant issued in connection with the Line of Credit (incorporated herein by reference to Exhibit 4.1 of the Company’s Current Report filed on Form 8-K with the United States Securities and Exchange Commission on November 3, 2016). NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM
November 3, 2016	EX-10.1	Promissory Note, dated October 26, 2016 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.
November 3, 2016	EX-99.1	Pressure BioSciences, Inc. Closes $2,000,000 Line-of-Credit Access to Capital will Enable the Company to Increase Its Focus on Growth and Stability FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President & CEO (508) 230-1828 (T) Jeffrey N. Peterson, Chairman (650) 812-8121 (T) Pressure BioSciences, Inc. Closes $2,000,000 Line-of-Credit Access to Capital will Enable the Company to Increase Its Focus on Growth and Stability South Easton, MA, November 3, 2016 ? Pressure BioSciences, Inc. (OTCQB: PBIO) (?PBI? and the ?Company?),
November 3, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2016 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (C
November 1, 2016	PRE 14A	Pressure BioSciences 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
August 15, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 [ ] Transition Repor UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-21615 PRESSUR
August 15, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 [ ] Transition Repor UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-21615 PRESSUR
May 16, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 [ ] Transition Repo UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0-21615 PRESSURE
April 6, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of i
April 5, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2015 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 000-21615 PRESSURE BI
March 31, 2016	NT 10-K	Pressure BioSciences 0-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2018 Estimated average burden hours per response?...????... 2.50 SEC FILE NUMBER 000-21615 CUSIP NUMBER (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended
March 7, 2016	EX-99.1	Pressure BioSciences Closes $550,000 First Tranche of $5 Million PIPE Over-Subscription Amount FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President & CEO, PBI (508) 230-1828 (T) Jeffrey N. Peterson, Chairman, PBI (650) 812-8121 (T) Redwood Investment Group (714) 978-4425 (T) Pressure BioSciences Closes $550,000 First Tranche of $5 Million PIPE Over-Subscription Amount South Easton, MA, March 1, 2016 ? Pressure BioSciences, Inc. (OTCQB: PBIO) (?PBI? and the ?Company?), a
March 7, 2016	8-K	Pressure BioSciences (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2016 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Comm
January 15, 2016	8-K	Pressure BioSciences (Current Report/Significant Event) FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2016 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorpor
January 15, 2016	EX-99.1	Pressure BioSciences Exceeds $5 Million PIPE Goal and Opens $1.25 Million Over-Subscription Amount EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President & CEO, PBI (508) 230-1828 (T) Jeffrey N. Peterson, Chairman, PBI (650) 812-8121 (T) Redwood Investment Group (714) 978-4425 (T) Pressure BioSciences Exceeds $5 Million PIPE Goal and Opens $1.25 Million Over-Subscription Amount South Easton, MA, January 11, 2016 ? Pressure BioSciences, Inc. (OTCQB: PBIO) (?PBI? a
January 15, 2016	SC 13G/A	PBIO / Pressure BioSciences, Inc. / Iliad Research & Trading, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pressure Biosciences, Inc. (Name of Issuer) Common Stock, par value $.01 (Title of Class of Securities) 74112E109 (CUSIP Number) Calendar Year 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
December 23, 2015	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2015 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction (Commission (IRS Em
December 17, 2015	EX-99.1	Pressure BioSciences Eliminates All Remaining Variable Rate (Floorless) Convertible Notes Company Closes Additional $730,000 of $5 Million PIPE; Funding Received to Date Reaches $4,755,000 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President & CEO, PBI (508) 230-1828 (T) Jeffrey N. Peterson, Chairman, PBI (650) 812-8121 (T) Redwood Investment Group (714) 978-4425 (T) Pressure BioSciences Eliminates All Remaining Variable Rate (Floorless) Convertible Notes Company Closes Additional $730,000 of $5 Million PIPE; Funding Received to Date Reaches $4,755,
December 17, 2015	8-K	Pressure BioSciences (Current Report/Significant Event) FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2015 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorpo
November 20, 2015	DEF 14A	Pressure BioSciences 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
November 12, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2015 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of
November 12, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 [ ] Transition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0-21615 PRES
November 9, 2015	PRE 14A	Pressure BioSciences 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
September 29, 2015	8-K	Pressure BioSciences (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2015 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation)
September 29, 2015	EX-99.1	Pressure BioSciences Closes Additional $1,100,000 of $5 Million PIPE; Total Funds Received to Date Reach $3,280,000 PIPE Proceeds Used to Eliminate 70% of Variable Rate Convertible Debt, Expand Marketing and Sales Capabilities, Add Manufacturing Pers FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President & CEO (508) 230-1828 (T) Jeffrey N. Peterson, Chairman (650) 812-8121 (T) Pressure BioSciences Closes Additional $1,100,000 of $5 Million PIPE; Total Funds Received to Date Reach $3,280,000 PIPE Proceeds Used to Eliminate 70% of Variable Rate Convertible Debt, Expand Marketing and Sales Capabilities, Add Manufacturing Person
August 18, 2015	8-K	Pressure BioSciences (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2015 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Co
August 18, 2015	EX-10.1	STOCK EXCHANGE AGREEMENT STOCK EXCHANGE AGREEMENT This Stock Exchange Agreement, dated as of the 24th day of July, 2015 (this ?Agreement?), by and between Pressure BioSciences Inc.
August 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 [ ] Transition Repor UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0-21615 PRESSURE
July 28, 2015	EX-3.1	Articles of Amendment to Restated Articles of the Organization of the Company
July 28, 2015	8-K	Pressure BioSciences (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2015 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Comm
July 28, 2015	EX-4.2	Form of Warrant NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM
July 28, 2015	EX-99.1	Pressure Biosciences Closes $2,180,000 Initial Tranche of a $5 Million Private Placement Senior Secured Convertible Debenture Offering Closed at Market Price with Common Stock Warrants Exercisable at a 43% Premium; Proceeds Will Support Expansion of FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President & CEO (508) 230-1828 (T) Jeffrey N. Peterson, Chairman (650) 812-8121 (T) Pressure Biosciences Closes $2,180,000 Initial Tranche of a $5 Million Private Placement Senior Secured Convertible Debenture Offering Closed at Market Price with Common Stock Warrants Exercisable at a 43% Premium; Proceeds Will Support Expansion of Ma
July 28, 2015	EX-10.2	Security Agreement SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of July 21, 2015 (this ?Agreement?), is among Pressure BioSciences, Inc.
July 28, 2015	EX-10.1	Subscription Agreement SUBSCRIPTION AGREEMENT AND INVESTOR QUESTIONNAIRE Minimum Offering of $1,500,000 Maximum Offering of $5,000,000 Senior Secured Convertible Debentures and Common Stock Warrants THE SECURITES OFFERED HEREBY ARE HIGHLY SPECULATIVE AND INVOLVE A HIGH DEGREE OF RISK AND IMMEDIATE DILUTION AND MAY BE PURCHASED ONLY BY PERSONS WHO QUALIFY AS ?ACCREDITED INVESTORS? UNDER RULE 501 (a) OF REGULATION D UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
July 28, 2015	EX-4.1	Form of Debenture NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE
June 26, 2015	EX-16.1	EX-16.1 pbioex161.htm Exhibit 16.1
June 26, 2015	8-K	Pressure BioSciences CURRENT REPORT (Current Report/Significant Event) pbio8k.htm UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2015 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporat
May 15, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21615 PRESSURE BIO
April 24, 2015	S-8	Pressure BioSciences REGISTRATION STATEMENT pbios8.htm As filed with the Securities and Exchange Commission on April 24, 2015 Registration No. 000-21615 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of 1933 PRESSURE BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Massachusetts 04-2652826 (State or Other Jurisdiction of Incorporation or Organization
April 24, 2015	EX-4.1	2013 Equity Incentive Plan.* pbioex41.htm EXHIBIT 4.1 PRESSURE BIOSCIENCES, INC. 2013 EQUITY INCENTIVE PLAN 1. Purpose and Eligibility. The purpose of this 2013 Equity Incentive Plan (the "Plan") of Pressure BioSciences, Inc., a Massachusetts corporation (the "Company") is to provide stock options, stock issuances and other equity interests in the Company (each, an "Award") to (a) employees, officers, directors, consultants a
March 31, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2014 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 000-21615 PRESSURE BIOSCI
February 11, 2015	EX-99.2	Investor Contacts: Richard T. Schumacher, President and CEO (508) 230-1828 (T) Nathan P. Lawrence, Vice President, Marketing and Sales (508) 230-1829 (F) Pressure BioSciences Receives First Purchase Order for its Barozyme HT48 High-throughput System Exhibit 99.2 FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President and CEO (508) 230-1828 (T) Nathan P. Lawrence, Vice President, Marketing and Sales (508) 230-1829 (F) Pressure BioSciences Receives First Purchase Order for its Barozyme HT48 High-throughput System Evaluation Program to End Early Following Placement of Three Additional Barozyme HT48 Systems; Accelerated Marketin
February 11, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2015 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Co
February 11, 2015	EX-99.1	EX-99.1 Exhibit 99.1
December 31, 2014	EX-4.1	SECURITIES PURCHASE AND EXCHANGE AGREEMENT Exhibit 4.1 SECURITIES PURCHASE AND EXCHANGE AGREEMENT This Securities Purchase and Exchange Agreement (this “Agreement”) is dated as of December , 2014, between Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”), and Clayton A. Struve (the “Purchaser”). WHEREAS, the Company has determined that it is in its best interests to issue shares of a newly created series of Preferred
December 31, 2014	EX-3.1	Articles of Amendment to Restated Articles of the Organization of the Company Exhibit 3.1
December 31, 2014	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2014 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (C
December 30, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K 1 pbio8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2014 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other j
December 29, 2014	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act OF 1934 Date of Report (Date of earliest event reported): December 19, 2014 PRESSURE BIOSCIENCES, INC.
November 19, 2014	DEF 14A	PBIO / Pressure BioSciences, Inc. DEF 14A - - PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin
November 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21615 PRESSURE
November 5, 2014	PRE 14A	PBIO / Pressure BioSciences, Inc. PRE 14A - - PRE 14A 1 pbiopre14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: þ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by
October 31, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2014 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Co
October 31, 2014	EX-99.1	EX-99.1 Exhibit 99.1
September 16, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2014 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (
September 16, 2014	EX-99.1	EX-99.1 Exhibit 99.1
August 25, 2014	EX-99.1	EX-99.1 Exhibit 99.1
August 25, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2014 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Com
August 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or o TRANSITION REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21615 PRESSURE BIOS
July 15, 2014	EX-99.1	1 Exhibit 99.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
July 15, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2014 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Massachusetts 000-21615 04-2652826 (State or other jurisdiction of incorporation) (Commi
June 13, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2014 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 0-21615 04-2652826 (Commiss
June 13, 2014	EX-99.1	Pressure BioSciences to Launch Its Much Anticipated High Throughput PCT-based Instrument System (the Barozyme HT48) at the Upcoming ASMS Annual Conference The Company Believes the Barozyme HT48 High Throughput System Can Significantly Fuel Growth and Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contacts: Richard T. Schumacher, President and CEO (508) 230-1828 (T) Nathan P. Lawrence, Vice President, Marketing and Sales Pressure BioSciences to Launch Its Much Anticipated High Throughput PCT-based Instrument System (the Barozyme HT48) at the Upcoming ASMS Annual Conference The Company Believes the Barozyme HT48 High Throughput System Can Significa
May 15, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014or o Transition Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 0-21615 PRESSURE BIOS
March 31, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2013 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 000-21615 PRESSURE BIOSCI
March 6, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2014 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 0-21615 04-2652826 (Com
February 5, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 29, 2014 PRESSURE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 0-21615 04-2652826 (Comm
January 28, 2014	SC 13G	PBIO / Pressure BioSciences, Inc. / Iliad Research & Trading, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Pressure Biosciences, Inc. (Name of Issuer) Common Stock, par value $.01 (Title of Class of Securities) 74112E109 (CUSIP Number) January 28, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
January 2, 2014	EX-10.1	SETTLEMENT AGREEMENT AND RELEASE Exhibit 10.1 SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release (this “Agreement”) is entered into as of December 26, 2013 (the “Effective Date”), by and between Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”), and Redwood Management LLC or its registered assigns (the “Holder”). The Company and Holder shall be referred to as the “Parties” and each a “Par
January 2, 2014	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act OF 1934 Date of Report (Date of earliest event reported): December 26, 2013 PRESSURE BIOSCIENCES, INC.
December 18, 2013	EX-10.1	PRESSURE BIOSCIENCES, INC. 2013 EQUITY INCENTIVE PLAN EXHIBIT 10.1 PRESSURE BIOSCIENCES, INC. 2013 EQUITY INCENTIVE PLAN 1. Purpose and Eligibility. The purpose of this 2013 Equity Incentive Plan (the "Plan") of Pressure BioSciences, Inc., a Massachusetts corporation (the "Company") is to provide stock options, stock issuances and other equity interests in the Company (each, an "Award") to (a) employees, officers, directors, consultants and advisors
December 18, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act OF 1934 Date of Report (Date of earliest event reported): December 12, 2013 PRESSURE BIOSCIENCES, INC.

PBIO / Pressure BioSciences, Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

मूलभूत आँकड़े

SEC Filings

SEC Filings (Chronological Order)